This study was designed to evaluate safety and tolerability of a range of doses of VE303 in healthy adult volunteers. The study also evaluated pharmacokinetics of intestinal colonization by the VE303 strains and pharmacodynamics of recovery of the gut microbiota after administration of antibiotics followed by a course of VE303.
VE303 is a rationally-defined bacterial consortium candidate being developed for the prevention of recurrent C. difficile infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under GMP conditions.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
39
The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
Pharmaron CPC
Baltimore, Maryland, United States
Safety of VE303 measured by incidence adverse events (AEs)
Measured in terms of incidence of AEs according to CTCAE V4.0
Time frame: 12 months post-dose
Tolerability of VE303 using modified PROMIS questionnaire (v1.0)
Characterized the highest well tolerated dose regimen of VE303 using modified PROMIS questionnaire (v1.0)
Time frame: 12 months post-dose
Evaluate the colonization of the intestinal microbiota with VE303 component bacteria
Measurement of VE303 strain colonization in stool samples was performed using a metagenomic sequencing-based bioinformatic approach. A strain-specific marker panel was employed to characterize the relative abundance of VE303 strains in the intestinal microbiota.
Time frame: 12 months post-dose
Evaluate the changes in the intestinal microbiota due to VE303 dosing.
Measurement of intestinal microbiota due to VE303 dosing was performed using metagenomic sequencing- and metabolomic analysis-based approaches. Thus, focusing on taxonomic and functional changes occurring in the gut.
Time frame: 12 months post-dose
Evaluate the metabolomic changes in stool due to VE303 dosing.
Quantified changes in pool of metabolite levels (bile acids and short-chain fatty acids) from stool samples
Time frame: 12 months post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.